Durham, NC, United States · North America
OncologyRare diseaseCell & gene therapyVaccines
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare diseaseVaccines
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyCell & gene therapyRare disease
NMPAFDA
SCALE 190 studies
Open to sponsorsSterile / advanced-therapy specialistView Durham, NC, United States · United States
Rare diseaseOncologyCell & gene therapy
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView OncologyVaccinesRare disease
NMPAFDAEMAPMDA
SCALE 270 studies
Open to sponsorsSterile / advanced-therapy specialistView Oncology
FDAEMAPMDANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyVaccines
PMDAFDAEMANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView E
Guildford, United Kingdom · Europe
OncologyRare disease
FDAEMAMHRA
SCALE 260 studies
Open to sponsorsAdvanced-therapy activeView Princeton, NJ, United States · United States
OncologyInfectious diseaseVaccines
FDAEMAMHRAHealth Canada
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView M
Cincinnati, OH, United States · United States
OncologyRare disease
FDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyCell & gene therapy
NMPAFDAEMAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView Morrisville, NC, United States · United States
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView OncologyRare disease
PMDAFDAEMANMPA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView PC
Zug, Switzerland · Europe
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 270 studies
Open to sponsorsAdvanced-therapy activeView London, United Kingdom · Europe
OncologyRare disease
FDAEMAPMDAMHRA
SCALE 230 studies
Open to sponsorsSelectiveView Not stated as a therapeutic-area list. The company names immuno-oncology and T-cell biology as biologics/discovery focus areas; its offering is otherwise described by modality (small moleculespeptidesoligonucleotidesmAbs
FDA
SCALE 00 studies
Open to sponsorsSelectiveView Oncology
EMAFDAMHRA
SCALE 240 studies
Open to sponsorsSelectiveView Oncology
PMDANMPAFDA
SCALE 260 studies
Open to sponsorsSelectiveView Oncology
FDANMPA
SCALE 220 studies
Open to sponsorsSelectiveView FDAPMDA
SCALE 00 studies
Open to sponsorsGeneral clinicalView Company states Integrated Drug Discovery services span "multiple therapeutic areas including but not limited to oncologyCNSmetabolic disorderspain & inflammation". Programme counts stated on the same page: Oncology 30+
SCALE 00 studies
Open to sponsorsGeneral clinicalView Oncology
PMDA
SCALE 200 studies
Open to sponsorsGeneral clinicalView Oncology
PMDAFDA
SCALE 120 studies
Open to sponsorsGeneral clinicalView FDAPMDA
SCALE 00 studies
Open to sponsorsGeneral clinicalView Irvine, United States · North America
Not presented as a therapeutic-area list. Company service pages name oncology (PDXCDXorthotopicsyngeneic
SCALE 00 studies
Open to sponsorsGeneral clinicalView Suzhou, China · North America
NMPAFDAEMA
SCALE 20 studies
Open to sponsorsGeneral clinicalView Company lists: Oncology & HematologyDermatologyNeuroscienceBiosimilar Development
SCALE 270 studies
Open to sponsorsGeneral clinicalView Company lists: OncologyFibrosisRespiratory DiseasesNeuroscience
SCALE 20 studies
Open to sponsorsGeneral clinicalView SCALE 00 studies
Open to sponsorsGeneral clinicalView Devens, United States · North America
SCALE 00 studies
Open to sponsorsGeneral clinicalView Nottingham, United Kingdom · Europe
SCALE 30 studies
Open to sponsorsGeneral clinicalView Nijmegen, Netherlands · Europe
SCALE 20 studies
Open to sponsorsGeneral clinicalView Stated on the company's Who We Are page: "multiple therapeutic areas with a specific focus on Inflammation & PainInfectious DiseasesCentral Nervous systemsand Oncology".
SCALE 00 studies
Open to sponsorsGeneral clinicalView